Vertex Pharmaceuticals Logo

Email this page: News Release

FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations

For security reasons, registration is required before you can use this feature.
* Indicates required field